1. Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer
   Thomas Albrecht et al, 2021, Cancers CrossRef
2. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
   Yana G Najjar, 2021, J Immunother Cancer CrossRef
3. Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD
   Zixuan Wang et al, 2022, BMC Immunol CrossRef
4. Effect of miR-206 Derived from Bone Marrow Mesenchymal Stem Cells (BMSCs) on CD8 Expression in Gastric Cancer
   He Bai et al, 2022, j biomater tissue eng CrossRef
5. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity
   Nicola Tumino et al, 2022, Front. Immunol. CrossRef
6. HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer
   Negin Karamali et al, 2022, Life Sciences CrossRef
7. PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
   Byung-Hyun Lee et al, 2022, Biomedicines CrossRef
8. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
   Xavier Thuru et al, 2022, Cancers CrossRef
9. CD155: A Key Receptor Playing Diversified Roles
   Shyam Sundar Nandi et al, 2022, CMM CrossRef
10. Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
    Yu-Hang Duan et al, 2022, Pharmaceutical Fronts CrossRef
11. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis
    Dan Zhang et al, 2022, World J Surg Onc CrossRef
12. Transcriptomic analysis of graft liver provides insight into the immune response of rat liver transplantation
    Wanyue Cao et al, 2022, Front. Immunol. CrossRef
13. Folate Receptor‐Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells
    Yi Lin et al, 2022, Small CrossRef
14. PVR—A Prognostic Biomarker Correlated with Immune Cell Infiltration in Hepatocellular Carcinoma
    Wen-Feng Liu et al, 2022, Diagnostics CrossRef
15. TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
    Shenhe Jin et al, 2022, Front. Oncol. CrossRef
16. Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment
    Jesus J. Benito-Lopez et al, 2023, Front. Oncol. CrossRef
17. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
    Kangdi Yang et al, 2023, Front. Immunol. CrossRef
18. null
    Sandro Matosevic, 2023 CrossRef
19. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
    Ornella Franzese et al, 2022, Cancers CrossRef
20. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells
    Xiaoqiang Gao et al, 2023, Clin Exp Med CrossRef
21. Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients
    Paula Kamińska et al, 2023, Cells CrossRef
22. Construction of a Combined Hypoxia-related Genes Model for Hepatocellular Carcinoma Prognosis
    Liping Ren et al, 2023, CAD CrossRef
23. Research advances in immune checkpoint drugs for non-small cell lung cancer
    Yue Shen et al, 2023, Journal of Drug Targeting CrossRef
24. Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
    Aleksandra Basek et al, 2023, Cancers CrossRef
25. Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
    Bao-Toan Nguyen Dang et al, 2024, Journal of Controlled Release CrossRef
26. Astragalus Polysaccharide Alleviates Ulcerative Colitis by Regulating the Balance of mTh17/mTreg Cells through TIGIT/CD155 Signaling
    Qi Wan et al, 2024, Molecules CrossRef
27. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE
    Junpeng Zhao et al, 2024, Lupus CrossRef
28. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
    Kyle B. Lupo et al, 2024, Nat Commun CrossRef
29. Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients
    Yu Zhou et al, 2024, Heliyon CrossRef
30. CD155 as an emerging target in tumor immunotherapy
    Jiang-Wan Wu et al, 2024, International Immunopharmacology CrossRef
31. Research Progress on the Study of Immune Checkpoints in Gastric Cancer
    艳霞 蒲, 2024, ACM CrossRef
32. Altered cancer metabolism and implications for next-generation CAR T-cell therapies
    Rishab Ramapriyan et al, 2024, Pharmacology & Therapeutics CrossRef
33. Immunotherapy of Clear-Cell Renal-Cell Carcinoma
    Sophie Grigolo et al, 2024, Cancers CrossRef